- Fee assured
- Verified this account
You'll need to contact this healthcare professional to check their availability
Dr Ferguson is a consultant Haematologist working at University Hospitals of North Midlands NHS trust. He specialises in treating patients with both malignant blood cancers and those with general, benign blood disorders. He has a particular interest in treating patients with myeloid and lymphoid malignancies and bone marrow transplantation. Dr Ferguson is the lead clinician for Haematology and Acute Oncology within the trust. He is strongly patient focused and dedicated to delivering the best in patient care.
Dr Ferguson graduated in Medicine from the University of Birmingham having previously attained a first class honours degree in Biomedical Science and a PhD in cancer research with a focus on molecular biology.
His haematology training was principally based at the Queen Elizabeth hospital in Birmingham. During this time he was appointed as an academic clinical lecturer and aligned clinical commitments with clinical research. His areas for research were the delivery of early phase clinical trials, bone marrow transplantation and basic scientific research into the genetics of acute myeloid leukaemia which he undertook at Oxford University and the University of Birmingham. He is an author on a number of high impact clinical research publications and has received a national award for his research.
Areas of interest
General benign haematological disorders; Myeloma; Lymphoma; Chronic Lymphocytic leukaemia; Myeloid disorders; Bone marrow transplantation; Bone marrow biopsy; Morphological analysis of blood and bone marrow; Patients aged 16 years and over
Current NHS consultant posts held
Clinical Lead for Haematology and Acute Oncology
University Hospitals of North Midlands NHS Trust
John Goldman Clinical Prize, British Society of Blood and Marrow Transplantation
Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Journal of Clinical Oncology. 2019 Mar 1;37(7):580-588.
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia is not Improved by Concurrent Vorinostat Therapy but is Predicted by a Diagnostic Molecular Signature.
Clinical Cancer Research. 2017 Nov 1;23(21):6430-6440
Allogeneic transplantation in primary refractory AML.
Bone Marrow Transplant. 2017 52:950-951.
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Haematologica. 2016 Nov;101(11):1351-1358.
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.
Blood Advances 2016 1:193-204.
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Biol Blood Marrow Transplant. 2016 Feb;22(2):385-90.
Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.
Leukemia. 2015 Dec;29(12):2404-7
Complete genome sequence and comparative metabolic profiling of the prototypical enteroaggregative Escherichia coli strain 042
PLoS One. 2010; 5(1): e8801.
The Escherichia coli biofilm-promoting protein Antigen-43 does not contribute to intestinal adhesion.
FEMS Microbiology Letters. 2008; 283 (2): 237-46.
Tyrosine Phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation.
Journal of Biological Chemistry. 2003; 278(34): 31972-9.
New interleukins: are there any more?
Current Opinion in Infectious Disease. 2003; 16(3): 211-7.
The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and anti-folates.
Cancer Research. 2002; 62(9): 2644-9.
Suppressors of cytokine signalling (SOCS) regulate cytokine and growth factor responses in the immune system.
Modern Aspects of Immunobiology. 2001; 2: 92-5.
Characterisation of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS and non-TS targeted chemotherapies.
Clinical Cancer Research. 2001 ; 7(11): 3533-9.
- BMedSci Queen's University of Belfast 1997
- PhD Queen's University of Belfast 2000
- MBChB University of Birmingham 2007
- MRCP Royal College of Physicians (London) 2011
- FRCPath Royal College of Pathologists 2016
Reference number 6155705
Professional bodies (positions held - last 3 yrs)
- Fellow of the Royal College of Pathologists Royal College of Pathologists 2016
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details